Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 27Parkinson Disease 4, Autosomal Dominant Lewy Body 24Neoplasms 14Melanoma 9Endometrial Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 7Thyroid Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Cholangiocarcinoma 6Stomach Neoplasms 4Recurrence 4Carcinoma 4Biliary Tract Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Paraganglioma, Extra-Adrenal 2Osteosarcoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Liver Neoplasms 2Glioma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, Hurthle cell 1

Interventions

Magnetic Resonance Spectroscopy 4Iodine-131 4Sunitinib 3dabrafenib 2Trastuzumab 2Thyrotropin Alfa 2Thyroidectomy 2Surgical Procedures, Operative 2Gefitinib 2Fluorodeoxyglucose F18 2Bortezomib 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1pralsetinib 1pembrolizumab 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1delta 24-sterol reductase 1copanlisib 1cediranib 1aldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Cancer, Papillary × lenvatinib × Clear all
NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Academic and Community Cancer Research United

Phase 2 Completed
57 enrolled 14 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡